This setting lets you change the way you view articles. You can choose to have articles open in a dialog window, a new tab, or directly in the same window.
Open in Dialog
Open in New Tab
Open in same window
Open in New Tab
Open in same window

Journal of Economic Literature: Vol. 50 No. 3 (September 2012)
JEL Volume. 50, Issue 3 |
Previous ArticleNext Article
Sign up for Email Alerts Follow us on Twitter Subscription Information
(Institutional Administrator Access)
JEL Forthcoming Articles
JEL Indexes (Members Only)
Full-text Article
Previous ArticleNext Article
Expand
Quick Tools:
Print Article Summary Email Link to this Article Export CitationSign up for Email Alerts Follow us on Twitter Subscription Information
(Institutional Administrator Access)
Explore:
JEL Forthcoming Articles
JEL Indexes (Members Only)Technology Growth and Expenditure Growth in Health Care
Article Citation
Chandra, Amitabh, and
Jonathan Skinner. 2012. "Technology Growth and Expenditure Growth in Health Care."
Journal of Economic Literature,
50(3): 645-80.
DOI: 10.1257/jel.50.3.645
DOI: 10.1257/jel.50.3.645
Abstract
In the United States, health care technology has contributed to rising survival rates, yet health care spending relative to GDP has also grown more rapidly than in any other country. We develop a model of patient demand and supplier behavior to explain these parallel trends in technology growth and cost growth. We show that health care productivity depends on the heterogeneity of treatment effects across patients, the shape of the health production function, and the cost structure of procedures such as MRIs with high fixed costs and low marginal costs. The model implies a typology of medical technology productivity: (I) highly cost-effective
"home run" innovations with little chance of overuse, such as anti-retroviral therapy for HIV, (II) treatments highly effective for some but not for all (e.g., stents), and (III) "gray area" treatments with uncertain clinical value such as ICU days among chronically ill patients. Not surprisingly, countries adopting Category I and effective Category II treatments gain the greatest health improvements, while countries adopting ineffective Category II and Category III treatments experience the most rapid cost growth. Ultimately, economic and political resistance in the
United States to ever-rising tax rates will likely slow cost growth, with uncertain effects on technology growth. (JEL H51, I11, I18, O31)
Article Full-Text Access
Full-text Article
Authors
Chandra, Amitabh (Harvard U)
Skinner, Jonathan (Dartmouth College)
Skinner, Jonathan (Dartmouth College)
JEL Classifications
H51: National Government Expenditures and Health
I11: Analysis of Health Care Markets
I18: Health: Government Policy; Regulation; Public Health
O31: Innovation and Invention: Processes and Incentives
I11: Analysis of Health Care Markets
I18: Health: Government Policy; Regulation; Public Health
O31: Innovation and Invention: Processes and Incentives

